279 related articles for article (PubMed ID: 23681892)
1. Molecular classification of non-small-cell lung cancer: diagnosis, individualized treatment, and prognosis.
Yu Y; He J
Front Med; 2013 Jun; 7(2):157-71. PubMed ID: 23681892
[TBL] [Abstract][Full Text] [Related]
2. Application of proteomics in non-small-cell lung cancer.
Cho WC
Expert Rev Proteomics; 2016; 13(1):1-4. PubMed ID: 26577456
[TBL] [Abstract][Full Text] [Related]
3. [Non-small cell lung cancer. New biomarkers for diagnostics and therapy].
Kayser G
Pathologe; 2015 Nov; 36 Suppl 2():189-93. PubMed ID: 26391246
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers in Non-Small Cell Lung Cancer: Perspectives of Individualized Targeted Therapy.
Aoki MN; Amarante MK; de Oliveira CEC; Watanabe MAE
Anticancer Agents Med Chem; 2018; 18(15):2070-2077. PubMed ID: 30147015
[TBL] [Abstract][Full Text] [Related]
5. Strategies for improving outcomes in NSCLC: a look to the future.
Stahel R; Peters S; Baas P; Brambilla E; Cappuzzo F; De Ruysscher D; Eberhardt WE; Felip E; Fennell D; Marchetti A; Paz-Ares L; Adjei AA
Lung Cancer; 2013 Dec; 82(3):375-82. PubMed ID: 24094287
[TBL] [Abstract][Full Text] [Related]
6. Gene expression profiling in non-small cell lung cancer: from molecular mechanisms to clinical application.
Petty RD; Nicolson MC; Kerr KM; Collie-Duguid E; Murray GI
Clin Cancer Res; 2004 May; 10(10):3237-48. PubMed ID: 15161676
[TBL] [Abstract][Full Text] [Related]
7. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies.
Li T; Kung HJ; Mack PC; Gandara DR
J Clin Oncol; 2013 Mar; 31(8):1039-49. PubMed ID: 23401433
[TBL] [Abstract][Full Text] [Related]
8. [Current morphological diagnosis of malignant lung tumors].
Junker K
Pathologe; 2006 Mar; 27(2):90-8. PubMed ID: 16435095
[TBL] [Abstract][Full Text] [Related]
9. SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015.
García-Campelo R; Bernabé R; Cobo M; Corral J; Coves J; Dómine M; Nadal E; Rodriguez-Abreu D; Viñolas N; Massuti B
Clin Transl Oncol; 2015 Dec; 17(12):1020-9. PubMed ID: 26691657
[TBL] [Abstract][Full Text] [Related]
10. Role of artificial intelligence in the care of patients with nonsmall cell lung cancer.
Rabbani M; Kanevsky J; Kafi K; Chandelier F; Giles FJ
Eur J Clin Invest; 2018 Apr; 48(4):. PubMed ID: 29405289
[TBL] [Abstract][Full Text] [Related]
11. Genomic medicine in non-small cell lung cancer: paving the path to personalized care.
Sriram KB; Larsen JE; Yang IA; Bowman RV; Fong KM
Respirology; 2011 Feb; 16(2):257-63. PubMed ID: 21044232
[TBL] [Abstract][Full Text] [Related]
12. Prognostic, therapeutic and diagnostic potential of microRNAs in non-small cell lung cancer.
Markou A; Liang Y; Lianidou E
Clin Chem Lab Med; 2011 Oct; 49(10):1591-603. PubMed ID: 21767219
[TBL] [Abstract][Full Text] [Related]
13. Bioinformatics analysis and experimental validation of TTK as a biomarker for prognosis in non-small cell lung cancer.
Chen J; Wu R; Xuan Y; Jiang M; Zeng Y
Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 32969465
[TBL] [Abstract][Full Text] [Related]
14. Precision Medicine in Non-Small Cell Lung Cancer: Current Standards in Pathology and Biomarker Interpretation.
Brown NA; Aisner DL; Oxnard GR
Am Soc Clin Oncol Educ Book; 2018 May; 38():708-715. PubMed ID: 30231309
[TBL] [Abstract][Full Text] [Related]
15. LungCARD - Report on worldwide research and clinical practices related to lung cancer.
Jankovic R; J Goncalves H; Cavic M; Clemente C; Lind M; Murillo Carrasco A; Nadifi S; Khyatti M; Adebambo T; Egamberdiev D
J BUON; 2019; 24(1):11-19. PubMed ID: 30941946
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive analyses of the heterogeneity and prognostic significance of tumor-infiltrating immune cells in non-small-cell lung cancer: Development and validation of an individualized prognostic model.
Pang Z; Chen X; Wang Y; Wang Y; Yan T; Wan J; Du J
Int Immunopharmacol; 2020 Sep; 86():106744. PubMed ID: 32623229
[TBL] [Abstract][Full Text] [Related]
17. Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer.
Signorovitch J; Zhou Z; Ryan J; Anhorn R; Chawla A
J Med Econ; 2019 Feb; 22(2):140-150. PubMed ID: 30430885
[TBL] [Abstract][Full Text] [Related]
18. Management of KRAS-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine.
Aredo JV; Padda SK
Curr Treat Options Oncol; 2018 Jun; 19(8):43. PubMed ID: 29951788
[TBL] [Abstract][Full Text] [Related]
19. Gene expression profiling of non-small-cell lung cancer.
Lacroix L; Commo F; Soria JC
Expert Rev Mol Diagn; 2008 Mar; 8(2):167-78. PubMed ID: 18366303
[TBL] [Abstract][Full Text] [Related]
20. Prognostic markers in resectable non-small cell lung cancer.
Strauss GM
Hematol Oncol Clin North Am; 1997 Jun; 11(3):409-34. PubMed ID: 9209903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
